Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis

Prostate

Volumn 68, Issue 15, 2008, Pages 1696-1706

  Raclaw, Kristin A ^a   Heemers, Hannelore V ^a   Kidd, Emily M ^a   Dehm, Scott M ^a   Tindall, Donald J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Androgen depletion independent (ADI); Androgen receptor; Apoptosis; TRAIL

Indexed keywords

FLICE INHIBITORY PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TESTOSTERONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANDROGEN; ANDROGEN RECEPTOR;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION; CELL COUNT; CELL NUCLEUS; CELL PROTECTION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENETIC TRANSFECTION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMINAL VESICLE; STAINING; TISSUE FIXATION; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; ORCHIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION; WISTAR RAT;

ANDROGENS; ANIMALS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CYTOPROTECTION; MALE; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; RECEPTORS, ANDROGEN; RNA, MESSENGER; RNA, SMALL INTERFERING; SEMINAL VESICLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 55249108322     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20844     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61(4):332-353.
3. Santos AF, Huang H, Tindall DJ. The androgen receptor: A potential target for therapy of prostate cancer. Steroids 2004;69(2):79-85.
4. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351(15):1488-1490.
5. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006;99(2):333-344.
6. Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, Black SC, Hornung F, Lenardo MJ, Hayden MR, Roy S, Nicholson DW. Cell death attenuation by "Usurpin", a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Diff 1998;5:271-288.
7. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 1997;272(28):17255-17257.
8. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J-L, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388(6638):190-195.
9. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 2005;280(15):14507- 14513.
10. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005;25(1):31-58.
11. Gao S, Lee P, Wang H, Gerald W, Adler M, Zhang L, Wang Y-F, Wang Z. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005;19(7):1792-1802.
12. Zhang X, Jin T-G, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004;64(19):7086-7091.
13. Hesry V, Claire P-P, Marion T, Ludovic T, Bernard J, Patard J-J, Thierry G. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 2006;66(9):987-995.
14. Heemers H, Vanderhoydonc F, Roskams T, Shechter I, Heyns W, Verhoeven G, Swinnen JV. Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol Cell Endocrinol 2003;205(1-2):21-31.
15. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62(4):1008-1013.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156-159.
17. Nastiuk KL, Kim JW, Mann M, Krolewski JJ. Androgen regulation of FLICE-like inhibitory protein gene expression in the rat prostate. J Cell Physiol 2003;196(2):386-393.
18. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A Compendium of old and new lines - Part 1. J Urol 2005;173(2):342-359.
19. Kang J, Bu J, Hao Y, Chen F. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis 2005;8(3):274-279.
20. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276(14):10767-10774.
21. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey S, Nwokorie C, Onwudiwe N, Srivastava R. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-6083.
22. Guseva N, Taghiyev A, Rokhlin O, Cohen M. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91(1):70-99.
23. Vlietstra RJ, van Alewijk DCJG, Hermans KGL, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58(13):2720-2723.
24. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: Present and future challenges. Expert Opin Ther Targets 2007;11(10):1299-1314.